Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 133 - 25 JULY 2022  In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 117/2022.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

DAMPSKIBSSELSKABET NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 132 - 25 jULY 2022 On 6 July 2022, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 6 July 2022 up to and including no later than 16 August 2022. For details, please see announcement no. 117 of 6 July 2022.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 15 million (approximately DKK 106 million). Under the

Trelleborg’s magazine T-Time – about solutions that seal, damp and protect critical applications

Trelleborg’s magazine T-Time has shifted to an online format and will no longer be printed and distributed by post to shareholders and other stakeholders. The online format lessens the environmental impact and takes advantage of the opportunities created by digitization and interactivity.   In the July edition one can read about:   A safe crossing Trelleborg’s sealing systems for immersed tunnels, with a life expectancy of 120 years, protect infrastructure against water ingress, ground movements and water pressure.   Keyhole surgery for pipes Customized solutions for

SimCorp A/S – Share buyback program

Company Announcement no. 34/2022On February 15, 2022 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR. In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 20.0m, to be executed during the period from February 15, 2022 to July 31, 2022. The following transactions have been executed under the program:          Date                 Number of shares

Outokumpu – Announcement regarding change in holdings

Outokumpu OyjStock exchange releaseJuly 25, 2022 at 10.45 am EESTOutokumpu – Announcement regarding change in holdings Outokumpu Oyj (business identity code: 0215254-2) has on July 22, 2022 received a notification based on Chapter 9, Section 5 of the Finnish Securities Market Act. Société Générale SA’s total holding in the shares and voting rights of Outokumpu has risen above 5% threshold and was 5.03% on July 21, 2022. Their earlier holding in the Outokumpu shares and voting rights was below minimum threshold. Total direct andindirect holdingsof SociétéGénérale SA

Company Announcement No. 83, 2022 – Debtor composition in Nordea Kredit (CK 92)

Monthly information on debtor composition in Nordea Kredit published in order to comply with the Transparency Directive's disclosure requirements.Nordea Kredit hereby publishes monthly data on debtor composition of all callable bond series. The information is subject to disclosure requirements in the Securities Trading Act § 27a section 1.The information is also published in the usual way via the Copenhagen Stock Exchange / OMX.   Nordea Kredit Realkreditaktieselskab   Klaus Johnbeck Phone : +45 55 47 05 11

Risk Intelligence A/S secures funding package

Risk Intelligence A/S (“Risk Intelligence” or "Company") has secured a loan funding package to provide capital for increased commercial initiatives and for general liquidity.During July and ending today 25 July, Risk Intelligence has secured a DKK 5.5M funding package in loans from private lenders of 3, 6, and 9 months duration, and at an interest rate of 12% PA. Some of the loans have an option to be renewed pending mutual agreement. The lenders are shareholders of Risk Intelligence A/S. This funding model was selected as other sources of funding were found to be more costly and with

iLOQ opens a new sales office in Poland

iLOQ, a provider of digital access management solutions, will continue to fulfill its growth strategy by expanding to Poland. Founded in Finland in 2003, iLOQ currently has sales offices in 9 countries throughout Europe, operations in Canada and a partner network around the world. Adding Poland to its portfolio continues to fulfill the Company’s growth strategy and allows iLOQ to introduce the benefits of its battery-free digital-locking and mobile-access-sharing technology to a new market. Grzegorz Korzeniowski has been appointed Country Manager in Poland. He will be

Preliminary study to detect immune complex and complement deposits in renal biopsies initiated with the University Hospitals Coventry and Warwickshire in the UK

A proof of concept-study to explore the potential of Lumito's UCNP to detect immune complex and complement deposits in renal biopsies has been initiated in collaboration with University Hospitals Coventry and Warwickshire NHS Trust in the UK and a research team led by Dr. Kishore Gopalakrishnan.Obtaining a renal biopsy is an invasive procedure but is nevertheless an important part of the management of renal disease. The diagnostic algorithm includes the detection of immunoglobulin and complement deposits in the kidney, primarily in the glomeruli. The conventional and well-established

Wulff Group Plc’s Half-Year Financial Report for January 1 – June 30, 2022

HALF-YEAR FINANCIAL REPORT | JULY 25, 2022 AT 9.30 A.M. This is a summary of Wulff Group Plc’s half-year financial report for January-June 2021. Wulff Group’s half-year financial report as a whole is attached as a PDF file to this stock exchange release and it is also available on the company’s website wulff.fi/en . Sales growing in the Nordic markets 1.4.–30.6.2022 BRIEFLY · Net sales increased in the Nordic countries in the Contract Customers Segment; domestically, net sales of international exhibition services and financial administration services

Bioservo receives a major customer order in the USA corresponding to SEK 1.6 million

Via the distributor Rhino Tool House, Bioservo Technologies AB has received a significant commercial order from Waupaca Foundry for 30 Ironhand® systems for an order value of SEK 1.6 million. The order is part of an implementation project where Bioservo together with the distributor Rhino Tool House, during six months, will validate the product for a wider implementation within the foundry industry.Waupaca Foundry is a leading supplier of iron castings and operates six iron foundries in North America. Many of the work steps in a foundry are manual and demanding for the workers. At Waupaca

Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations.AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the PATHFINDER

Tezspire recommended for EU approval in asthma

25 July 2022 07:10 BST Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations AstraZeneca's Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The Committee for Medicinal Products

Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis

First and only long-acting C5 complement inhibitor showed early effect and demonstrated clinical improvement in activities of daily living.Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. If authorised, Ultomiris would be the first and only approved long-acting C5 complement inhibitor for the treatment of AChR antibody-positive gMG in the EU. The Committee for

Ultomiris recommended for EU approval for gMG

25 July 07:05 BST Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis First and only long-acting C5 complement inhibitor showed early effect and demonstrated clinical improvement in activities of daily living Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. If authorised, Ultomiris would be the first

Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer

Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu is the first HER2-directed therapy to demonstrate a survival benefit in this population. Application being evaluated under FDA Real-Time Oncology Review and Project Orbis.AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridisation [ISH]-negative) breast

High-Performance High-Value Forte™ Sim Racing Pedal Set from Asetek SimSports™ Now Shipping

Advanced Load-Cell Brake Pedals from Asetek for Immersive Sim RacingAalborg, Denmark – July 25, 2022 –– Asetek, sim racing gear innovator, the creator of the all-in-one liquid cooler, and the global leader in liquid cooling solutions for gaming PCs and DIY enthusiasts, today announced it has started shipping its high-performance Forte™ Throttle and Brake Pedal Set for immersive sim racing. Forte means “strong” and with the Forte™ Pedal Set from Asetek SimSports™ aspiring sim racers can experience high-end pedals for immersive racing at a very competitive price point, while still providing a

First day of trading in Collector Bank is expected to be on 15 August 2022 – Collector AB applies for delisting

After the approval from the Swedish Financial Supervisory Authority on 21 July 2022 that the intra-group merger between Collector AB (publ) (”Collector AB”) and Collector Bank AB (”Collector Bank”) may be executed, the Board of Collector AB has resolved to apply for delisting of the shares in Collector AB from Nasdaq Stockholm. Nasdaq Stockholm has previously approved the listing of the shares in Collector Bank subject to customary conditions. Collector AB hereby informs of a preliminary timetable. The merger is expected to be completed on 15 August 2022.The Swedish Financial Supervisory

Interim Report 1 January - 30 June 2022

Strong quarter despite increased uncertaintySECOND QUARTER The second quarter of the year was strong in terms of profitability and EBITDA amounted to SEK 173 million compared with SEK 146 million the previous year. Net sales during the quarter amounted to SEK 1,009 million, compared with SEK 826 million last year, an increase of 22%. The higher net sales are explained by higher sales prices for all products and increased sales volumes in the Joinery product area.   The improved result compared to the previous year is explained by higher sales prices for Sawn Wood, increased sales

Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer

25 July 2022 07:00 BST Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo's Enhertu is the first HER2-directed therapy to demonstrate a survival benefit in this population Application being evaluated under FDA Real-Time Oncology Review and Project Orbis AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the

GomSpace (provider of nanosatellites) announces its quarterly results for the second quarter 2022

Stockholm, July 25, 2022. GomSpace Group AB (the “Company”) announces its interim report for the second quarter of 2022. The report is available on the Company’s homepage (www.gomspace.com). The following is taken from the quarterly report: Second quarter summary 1 April – 30 June 2022 (2021) · Order intake decreased by 78% to T.SEK 43,931 (199,459) The decrease is due to GomSpace in 2021 signed a large contract with Indra of EUR 14,5 million (147 million SEK) · Net revenues increased by 8% to T.SEK 51,253 (47,535) · Gross margin decreased to 6% (14%) · Operating profit (

Vinted UAB announces a recommended public offer of SEK 14.10 in cash per share to the shareholders of Rebelle AB (publ)

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or the United States or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important

Adolescent arterial stiffness – a novel risk factor for hypertension and insulin resistance in young adulthood and for type 2 diabetes mellitus in mid-adulthood

Emerging evidence suggests that arterial stiffness may be a novel risk factor to be targeted in the prevention and treatment of vascular and metabolic diseases from a young age, a review of studies published in the Journal of Hypertension concludes.The prevalence of hypertension and obesity has been on the increase globally, despite the targeted effort at promoting weight loss, increasing physical activity, and decreasing sedentary time in the general population. This global challenge informed a recent scientific statement from the American Heart Association on further research into obesity

There are no items matching the current filter
There are no more items matching the current filter
Back to top